News
AKYA
1.130
0.00%
0.000
FORM 10-K" This is an annual report filed by Akoya Biosciences, Inc. with the United States Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2024.
Press release · 4d ago
Weekly Report: what happened at AKYA last week (0331-0404)?
Weekly Report · 4d ago
AKOYA BIOSCIENCES - ON APRIL 2, ENTERED SECURITIES PURCHASE AGREEMENT WITH QUANTERIX CORPORATION
Reuters · 04/04 12:36
AKOYA BIOSCIENCES INC -PURSUANT TO SECURITIES PURCHASE AGREEMENT, CO TO ISSUE CONVERTIBLE NOTES UP TO $30 MILLION - SEC FILING
Reuters · 04/04 12:36
Quanterix: Still Many, Many Questions
Seeking Alpha · 04/02 13:41
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion As Foundational Spatial Proteomics Technology For Large-Scale Study To Address Cancer Inequities
Benzinga · 04/02 12:23
Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion
TipRanks · 04/02 12:16
Weekly Report: what happened at AKYA last week (0324-0328)?
Weekly Report · 03/31 09:01
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Benzinga · 03/26 13:57
Tikvah intends to vote against Quanterix’s proposed merger with Akoya
TipRanks · 03/25 19:34
Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens
TipRanks · 03/25 19:05
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 03/25 15:11
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 03/25 14:57
Akoya Biosciences Cut to Equal-Weight From Overweight by Stephens & Co.
Dow Jones · 03/25 14:42
Akoya Biosciences Price Target Cut to $1.80/Share From $3.50 by Stephens & Co.
Dow Jones · 03/25 14:42
Stephens & Co. Downgrades Akoya Biosciences to Equal-Weight, Lowers Price Target to $1.8
Benzinga · 03/25 14:32
AKOYA BIOSCIENCES INC <AKYA.O>: STEPHENS CUTS TO EQUAL-WEIGHT FROM OVERWEIGHT; CUTS TARGET PRICE TO $1.8 FROM $3.5
Reuters · 03/25 10:45
Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance
TipRanks · 03/25 10:17
TIKVAH MANAGEMENT- ANNOUNCES INTENTION TO VOTE AGAINST QUANTERIX'S PROPOSED MERGER WITH AKOYA BIOSCIENCES
Reuters · 03/24 12:02
Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges
TipRanks · 03/24 10:45
More
Webull provides a variety of real-time AKYA stock news. You can receive the latest news about Akoya Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AKYA
More
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).